10.08.2011 • NewsLonzaunder construction

Lonza To Build Formulation Plant in Visp

Lonza said it will be investing CHF 5.8 million in a formulation plant for its Meta metaldehyde in Visp, Switzerland. The company said the plant will enable it to supply its own formulations, allowing Lonza to serve the market with metaldehyde as an active substance, as well as with ready-made slug pellets.

The plant is expected to come online in the second half of 2012.

 

Company

Logo:

Lonza AG

Muenchensteinerstrasse 38
4002 Basel
Switzerland

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read